ArticleCancer discovery2019
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Erratum issuedAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Multilevel Mechanisms of Cancer Drug Resistance.International journal of molecular sciences · 2024Pooled it
- Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.Cancer medicine · 2019Pooled it
- BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities.Cancer science · 2026Review
- Article
- Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy.Pharmaceutics · 2025Review
- A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases.Acta neuropathologica communications · 2025Article
- Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.Molecular cancer · 2025Review
- PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.Cancer research · 2025Article
- Interplay between MAPK signaling pathway and autophagy in skin aging: mechanistic insights and therapeutic implications.Frontiers in cell and developmental biology · 2025Review
- Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis.Frontiers in molecular biosciences · 2025Article
- Treatment resistance to melanoma therapeutics on a single cell level.Scientific reports · 2024Article
- Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.Oncotarget · 2024Article
- Overcoming Cancer Persister Cells by Stabilizing the ATF4 Promoter G-quadruplex.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Purinergic CaCancers · 2024Article
- RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2024Review
- MAPK-mediated PHGDH induction is essential for melanoma formation and represents an actionable vulnerability.bioRxiv : the preprint server for biology · 2024Article
- Effects of Individual Essential Amino Acids on Growth Rates of Young Rats Fed a Low-Protein Diet.Animals : an open access journal from MDPI · 2024Article
- HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis through a non-canonical pathway in intestinal ischemia/reperfusion.Cell death & disease · 2024Article
- Mechanism of action and treatment of type I interferon in hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
28 authors.
Rani OjhaAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Nektaria M LeliDepartment of Radiation Oncology, Smilow Center for Translational Research, University of Pennsylvania, Philadelphia, Pennsylvania.
Angelique OnoratiAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Shengfu PiaoAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ioannis I VerginadisDepartment of Radiation Oncology, Smilow Center for Translational Research, University of Pennsylvania, Philadelphia, Pennsylvania.
Feven TameireDepartment of Radiation Oncology, Smilow Center for Translational Research, University of Pennsylvania, Philadelphia, Pennsylvania.
Vito W RebeccaAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Cynthia I ChudeAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-8595-9151
Sengottuvelan MuruganAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Colin FennellyAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Estela Noguera-OrtegaAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-6507-0673
Charleen T ChuDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania
Shujing LiuAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Xiaowei XuDepartment of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania.
Clemens KreplerMolecular and Cellular Oncogenesis Program and Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania.
Min XiaoMolecular and Cellular Oncogenesis Program and Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania.
Wei XuAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Zhi WeiDepartment of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.ORCID 0000-0001-6059-4267
Dennie T FrederickMassachusetts General Hospital, Harvard University, Boston, Massachusetts.
Genevieve BolandMassachusetts General Hospital, Harvard University, Boston, Massachusetts.ORCID 0000-0002-7522-6173
Tara C MitchellAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Giorgos C KarakousisDepartment of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Lynn M SchuchterAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Keith T FlahertyMassachusetts General Hospital, Harvard University, Boston, Massachusetts.
Gao ZhangMolecular and Cellular Oncogenesis Program and Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania.
Meenhard HerlynMolecular and Cellular Oncogenesis Program and Melanoma Research Center, Wistar Institute, Philadelphia, Pennsylvania.
Constantinos KoumenisDepartment of Radiation Oncology, Smilow Center for Translational Research, University of Pennsylvania, Philadelphia, Pennsylvania.
Ravi K AmaravadiAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Ravi.amaravadi@uphs.upenn.edu.
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MTumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1M Tissue &PathologyP50CA093372 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2001 to 2009
$15.4MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MUPR, interferon signaling and tumorigenesisP01CA165997 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KOUMENIS, CONSTANTINOS · 2013 to 2023
$10.9MRegulation of Autophagy & Mitochondrial Recycling in Neuronal Cell Death- SupplementR01AG026389 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHU, CHARLEEN T · 2007 to 2024
$6.0MMolecular mechanisms of BRAF inhibitor induced UPR and autophagyR01CA198015 · NCI · UNIVERSITY OF PENNSYLVANIA · PI AMARAVADI, RAVI K · 2015 to 2019
$1.8MHLTF gene silencing: a novel determinant of sensitivity to autophagy inhibitionR01CA169134 · NCI · UNIVERSITY OF PENNSYLVANIA · PI AMARAVADI, RAVI K · 2013 to 2017
$1.7MNCI NIH HHS P01 CA114046NCI NIH HHS P01 CA128814NCI NIH HHS P01 CA165997NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA093372NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA169134NCI NIH HHS R01 CA198015NIA NIH HHS R01 AG026389
Abstract
Resistance to BRAF and MEK inhibitors (BRAFi + MEKi) in
Indexed as
MAP Kinase Signaling SystemMutationAnimalsAutophagyCell Line, TumorDrug Resistance, NeoplasmEndoplasmic ReticulumEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHumansMaleMAP Kinase Kinase KinasesMelanomaMiceMice, Inbred NODMice, SCIDBRAF protein, humanEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mouseMAP Kinase Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.